In contrast to harnessing inflammatory conditions with LD IL-2, high-dose IL-2 (HD IL-2) formulations were used to combat malignant tumors, for example in melanoma and renal cancer patients [199,200,201]. The gene discussed is IL2; the disease is renal carcinoma.